Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer
This is an open label, Phase 1, dose escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab in patients with immune checkpoint inhibitor refractory non-small cell lung cancer.
Lung Cancer
BIOLOGICAL: TILT-123|BIOLOGICAL: KEYTRUDAÂ®
Dose Escalation Phase, Incidence of DLT AEs in subjects with refractory NSCLC, Day 1 to Day 85|Incidence of Adverse Events, Determine the safety and tolerability of the combination of TILT-123 and Pembrolizumab in patients with refractory non-small cell lung cancer by evaluating the number, frequency, and severity of adverse events using CTCAE v 5.0., Day 1 to Day 85
Dose Escalation Phase MTD, Determine the Maximum Tolerated Dose in patients with refractory NSCLC, Day 1 to Day 85
This is an open label, Phase 1, dose escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab in patients with immune checkpoint inhibitor refractory non-small cell lung cancer.